Long‐term safety and efficacy of secukinumab in paediatric severe plaque psoriasis: 236‐week, Phase 3 trial results
These findings support the sustained efficacy and favourable safety profile of secukinumab in paediatric patients with severe plaque psoriasis over a 236-week treatment period.
Authors
- Külli Kingo (ORCID: https://orcid.org/0000-0001-6301-9612)
- Swapnil Dahale
- Michael Ziv (ORCID: https://orcid.org/0000-0003-4762-899X)
- Bertrand Paguet
- Andrzej Kaszuba
- Nina Magnolo (ORCID: https://orcid.org/0000-0001-6802-0153)
- Dorota Krasowska (ORCID: https://orcid.org/0000-0002-3176-9870)
- Amita Bansal (ORCID: https://orcid.org/0000-0001-8716-9922)
- Ruvie Martin
- Shoba Ravichandran
- P. Papanastasiou
- Raúl de Lucas Laguna
Institutions
- Medical University of Lublin (PL)
- Novartis (Switzerland) (CH)
- Emek Medical Center (IL)
- Hospital Universitario La Paz (ES)
- Tartu University Hospital (EE)
- IQVIA (India) (IN)
- University Hospital Münster (DE)
- Novartis (United States) (US)
- Medical University of Lodz (PL)
- Tris Pharma (United States) (US)
- University of Tartu (EE)
Publication Details
- Journal
- Journal of the European Academy of Dermatology and Venereology
- Published
- 2025-11-15
- DOI
- https://doi.org/10.1111/jdv.70155
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 0.00